Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy.

@article{Galsky2011TreatmentOP,
  title={Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy.},
  author={Matthew D Galsky and Noah M. Hahn and Jonathan E Rosenberg and Guru P. Sonpavde and Thomas Hutson and William K. Oh and Robert Dreicer and Nicholas J Vogelzang and Cora N Sternberg and Dean F Bajorin and Joaquim Bellmunt},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 17},
  pages={
          2432-8
        }
}
  • Matthew D Galsky, Noah M. Hahn, +8 authors Joaquim Bellmunt
  • Published 2011
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • PURPOSE Cisplatin-based combination chemotherapy is considered standard first-line treatment for patients with metastatic urothelial carcinoma. However, a large proportion of patients with metastatic urothelial carcinoma are considered "unfit" for cisplatin. The purpose of this review is to define unfit patients and to identify treatment options for this subgroup of patients. PATIENTS AND METHODS In this review, the criteria used to define unfit patients are explored and the results of… CONTINUE READING
    View PDF
    180 Citations
    3 Highly Influenced Papers
    77 Cite Background
    10 Cite Methods
    4 Cite Results

    Paper Mentions

    INTERVENTIONAL CLINICAL TRIAL
    hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study"
    Cabozantinib plus Durvalumab in patients with advanced and chemotherapy-treated bladder carcinoma, of urothelial and non-urothelial histology: an open-label, single-centre, phase 2… Expand
    ConditionsBladder Carcinoma
    InterventionDrug
    Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
    April 2019 - February 2023
    INTERVENTIONAL CLINICAL TRIAL
    Avelumab Plus Carboplatin-gemcitabine in Urothelial Carcinoma
    Phase II Multicentre, randomized, open-label study to evaluate the safety and efficacy of avelumab with gemcitabine/carboplatin versus gemcitabine/carboplatin alone in patients with… Expand
    ConditionsMetastatic Urothelial Cancer
    InterventionCombination Product
    Associació per a la Recerca Oncologica, Spain
    May 2018 - April 2020

    Citations

    Publications citing this paper.
    SHOWING 1-10 OF 180 CITATIONS, ESTIMATED 29% COVERAGE

    [Urothelial cancer: update on systemic treatment options].

    VIEW 2 EXCERPTS
    CITES BACKGROUND

    Administration of cisplatin-based chemotherapy for advanced urothelial carcinoma in the community.

    VIEW 1 EXCERPT
    CITES BACKGROUND

    Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer

    VIEW 2 EXCERPTS
    CITES RESULTS & BACKGROUND

    Cisplatin Ineligibility for Patients With Metastatic Urothelial Carcinoma: A Survey of Clinical Practice Perspectives Among US Oncologists

    VIEW 3 EXCERPTS
    CITES RESULTS & BACKGROUND

    Systemic chemotherapy in patients with advanced transitional cell carcinoma of the urothelium and impaired renal function.

    Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens.

    The Role of Genomics in the Management of Advanced Bladder Cancer

    Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy.

    VIEW 2 EXCERPTS
    CITES METHODS

    Update on the Treatment of Metastatic Urothelial Carcinoma

    VIEW 2 EXCERPTS

    A phase II study of gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the bladder

    VIEW 1 EXCERPT
    CITES BACKGROUND

    FILTER CITATIONS BY YEAR

    2011
    2020

    CITATION STATISTICS

    • 3 Highly Influenced Citations

    • Averaged 32 Citations per year from 2018 through 2020

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 63 REFERENCES

    Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer.

    Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma.

    Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma.

    A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy.

    VIEW 1 EXCERPT

    Gemcitabine plus epirubicin in patients with advanced urothelial carcinoma who are not eligible for platinum-based regimens.

    VIEW 1 EXCERPT

    Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group.

    VIEW 1 EXCERPT

    Vinorelbine and oxaliplatin in stage IV nonsmall cell lung cancer patients unfit for cisplatin: a single-center experience.

    VIEW 1 EXCERPT

    A carboplatin-based regimen for the treatment of patients with advanced transitional cell carcinoma of the urothelium.

    Gemcitabine plus vinorelbine chemotherapy in patients with advanced bladder carcinoma who are medically unsuitable for or who have failed cisplatin-based chemotherapy.

    VIEW 1 EXCERPT

    Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial.

    VIEW 2 EXCERPTS